Xencor was founded in 1997 to commercially leverage work performed at Caltech by Dr. Bassil Dahiyat and Dr. Stephen Mayo in the area of proteins and Protein Design Automation.
From the company’s press release:
Xencor, Inc. and MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor. The trial is designed to assess the drug’s safety, tolerability, pharmacokinetic profile and preliminary anti-tumor activity in chronic lymphocytic leukemia (CLL) patients. The open-label, multi-dose, single-arm, dose-escalation study is estimated to enroll 30 patients suffering from relapsed or refractory CLL. More information on the trial can be found by searching for XmAb5574 at http://www.clinicaltrials.gov. read full press release